U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363642) titled 'Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab' on Nov. 25, 2025.
Brief Summary: This study aims to explore the potential for Tezepelumab-treated severe asthmatic patients to effectively and safely reduce their background maintenance medication while maintaining asthma symptom control.
Study Start Date: Jan. 31
Study Type: INTERVENTIONAL
Condition:
Severe Asthma
Intervention:
DRUG: Tezepelumab
Severe asthma taking medium-high dose ICS/LABA with up to one additional controller will be enrolled into this single arm treatment
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curat...